“Are peptides legal?” is the most common question in this market and the least answerable one, because it is malformed. Legal for whom to do what? Insulin is a peptide. So is the semaglutide in an approved prescription pen. So is the copper peptide in a face serum, and so is the unlabelled vial that arrived from an overseas seller with “not for human consumption” printed on the side.
All four are peptides. Only some of them are lawful, and the thing that separates them is not chemistry. It is a short stack of statutes that most operators have never actually read. Here they are.
Layer 1: the drug definition, and why your website decides it
Section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act defines a drug as an article intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, or intended to affect the structure or any function of the body.
The operative word is intended. The FDA’s intended use regulation looks at objective evidence of what you meant the product for — labelling, advertising, oral and written statements, the circumstances of sale, and what your customers are known to use it for. A disclaimer that contradicts the rest of your marketing does not win that argument. It just tells the reviewer you knew.
This is why two identical vials of the same substance can have different legal statuses. The chemistry is the same. The intended use is not.
Layer 2: approval
Section 201(p) defines a “new drug” as one not generally recognised among qualified experts as safe and effective for its labelled conditions of use. Essentially every peptide in the wellness market meets that definition, because general recognition requires published, adequate and well-controlled studies — a bar that animal data and clinic anecdote do not clear.
Section 505(a) then prohibits introducing an unapproved new drug into interstate commerce, and section 301(d) makes doing so a prohibited act. Section 502(f)(1) adds a second, independent problem: a prescription drug shipped without adequate directions for lay use is misbranded, and the exemption that normally solves that requires an approved application. Unapproved injectables sold direct to consumers typically violate both at once.
If you want the fuller version of what “approved” does and does not mean, read what “FDA approved” actually means.
Layer 3: the two compounding exemptions
Compounding is how lawfully-made non-approved preparations reach patients. Sections 503A and 503B carve out narrow exemptions from approval, adequate directions and CGMP requirements — but only on conditions.
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Prescription | Patient-specific, valid prescription required | Not required; may supply office stock |
| Registration | State-licensed pharmacy | Registers with FDA, subject to inspection |
| Manufacturing standard | USP compounding standards | CGMP |
| Bulk substances | Must appear on an approved list, have a USP monograph, or be a component of an approved drug | Must be on the 503B bulks list or be in shortage |
That last row is where peptides live or die. The pathway works by inclusion. A substance that appears on no list has not thereby been permitted — it has simply not been permitted. Absence is not permission, and this is the single most expensive misunderstanding in the sector.
Layer 4: the supplement door, which is closed for most peptides
The Dietary Supplement Health and Education Act created a separate, far lighter category — but you have to qualify to enter it. A supplement must contain a dietary ingredient, and a synthetic peptide developed as a drug candidate generally is not one. Where an ingredient is genuinely new, a New Dietary Ingredient notification supported by safety evidence must be filed before marketing.
Very few of the peptides sold in capsule form have done any of this. See peptides are not supplements.
Layer 5: the growth hormone felony almost nobody mentions
This one deserves its own heading because operators routinely walk into it without knowing it exists.
Under 21 U.S.C. § 333(e), knowingly distributing — or possessing with intent to distribute — human growth hormone for any use in humans other than the treatment of a disease or recognised medical condition that is authorised under section 505 and prescribed by a physician is a federal crime, punishable by up to five years in prison. The maximum doubles where a person under 18 is involved, and a conviction is treated as a felony violation of the Controlled Substances Act for asset forfeiture purposes, even though hGH is not itself a scheduled drug.
Anti-ageing, bodybuilding, recovery and general wellness are not “recognised medical conditions.” A clinic selling hGH for those purposes is not making a compliance error at the margin. It is committing a felony that Congress wrote a bespoke provision to reach.
Growth hormone secretagogues — the CJC-1295, ipamorelin and MK-677 family — are frequently marketed as the way around § 333(e). They are outside that specific provision. They are squarely inside layers 1 and 2 as unapproved new drugs.
Layer 6: controlled substances, usually not — but check
Most peptides are not scheduled under the Controlled Substances Act, so the DEA framework does not usually apply. That changes the moment a programme adds testosterone, which is Schedule III — at which point telehealth prescribing sits inside a different and time-limited set of rules. See the December 2026 telemedicine deadline.
Layer 7: state law, sitting on top of all of it
Federal law tells you whether a product may exist. State law tells you whether you may be the one providing it. Corporate practice of medicine doctrine governs who may own the entity that practises. Medical and nursing board rules govern who may examine, order and inject. State pharmacy boards govern what a compounding pharmacy in that state may ship and to whom. None of this is preempted by getting the federal layer right.
Layer 8: advertising law, sitting on top of that
The Federal Trade Commission requires that health claims be truthful and substantiated by competent and reliable scientific evidence at the time they are made. This applies to your website, your ads, your affiliate partners and the testimonials you republish. A claim can be simultaneously a drug claim to the FDA and a deceptive claim to the FTC, and the two agencies have a long history of acting jointly.
The five-question test
Before any peptide goes on your menu:
- Is it an FDA-approved drug for the use I intend? If yes, most of this collapses into ordinary practice.
- If not, is there a completed compounding pathway — on a bulks list, a USP monograph, or a component of an approved drug?
- What is my strongest published claim, and does it convert the product into a drug?
- Does any state I operate in restrict who may own, order, or administer this?
- Can I evidence every claim I make, today, in writing?
If any answer is “I assume so,” it is not an answer.
Where MDside sits
We maintain the formulary for the practices we support, confirm the supplying pharmacy’s specific authority in writing rather than by phone, and structure the entity so the ownership and delegation questions have documented answers before a patient is seen. Where a substance has no completed pathway, our providers do not prescribe it.
See how our peptide programs are structured, or start with the five lawful shapes a peptide brand can take.
Related reading
Frequently asked questions
Are peptides legal to buy in the United States?
Some are: approved peptide drugs are lawfully dispensed on prescription every day, and cosmetic peptides are sold over the counter. Unapproved injectable peptides sold to consumers are a different matter, and the fact that a website will take your money says nothing about legality.
Is it legal for a doctor to prescribe peptides?
A physician may prescribe an approved drug off-label, which is ordinary medical practice. Prescribing a substance that is not approved and has no completed compounding pathway is not off-label use — there is no approved label to be off.
Does “not for human consumption” make it legal to sell?
No. Intended use is determined from the whole marketing context, and the FDA has rejected that disclaimer in warning letters repeatedly. It is evidence of knowledge, not a defence.
Are peptides controlled substances?
Most are not scheduled. Human growth hormone is separately criminalised for non-medical distribution under 21 U.S.C. § 333(e), and any programme that includes testosterone brings the DEA framework with it.
If the FDA has not banned a peptide, can I use it?
No. The compounding pathway operates by inclusion on a list, not by omission from one. A substance nobody has prohibited by name is still an unapproved new drug.
General information about federal and state drug regulation, not legal advice. Statutory citations are given so you can read the source; how they apply to a specific product or practice is a question for counsel. Peptide status is actively changing — verify current FDA position before acting.